3.1 Asthma and COPD: Diagnosis, Staging, and Acute Exacerbation Protocols

Key Takeaways

  • In typical asthma, seek objective evidence of variable expiratory airflow. GINA 2026 accepts an adult FEV₁ or FVC increase of ≥12% and ≥200 mL. FeNO can support Type 2 asthma. GOLD uses post-bronchodilator FEV₁/FVC <0.70 in the appropriate COPD context.

  • In severe acute asthma, a silent chest, exhaustion, PEF <33%, SpO₂ <92% or unexpectedly normal arterial CO₂ is a life-threatening warning.

  • Irish NCEC guidance targets SpO₂ 94–98% for hypoxaemic severe adult asthma and initially 88–92% in acute hypoxaemic COPD with risk of hypercapnia. The GINA 2026 acute asthma target is 92–95% in patients aged six and over receiving supplemental oxygen.

  • Irish adult guidance uses oral prednisolone 40–50 mg early in acute asthma and 40 mg daily for five days in hospital-treated COPD exacerbations. In COPD, HSE community guidance advises considering antibiotics for increased dyspnoea with increased sputum volume or purulence.

  • Persistent acute COPD respiratory acidosis after controlled oxygen and initial therapy supports bilevel NIV when the airway can be protected. Severe acidosis or clinical deterioration calls for urgent critical-care assessment and prompt escalation if needed.

Last updated: November 2026

Diagnostic Distinction: Asthma vs. Chronic Obstructive Pulmonary Disease

Distinguishing between asthma and chronic obstructive pulmonary disease (COPD) represents one of the most critical clinical tasks in respiratory medicine. While both disorders manifest with dyspnoea, cough, wheeze, and expiratory airflow obstruction, their underlying immunological drivers, clinical courses, and therapeutic responses diverge substantially.

Clinical and Pathophysiological Profiles

  • Asthma is a chronic inflammatory disorder of the conducting airways with several inflammatory phenotypes. Type 2 inflammation, including eosinophils and mast cells, is common in allergic asthma. Airflow limitation is characteristically variable, episodic, and reversible (either spontaneously or pharmacologically). Patients frequently describe marked diurnal variability, with cough and chest tightness waking them in the early hours of the morning or late at night. Symptoms are triggered by specific allergens (aeroallergens, animal dander), cold air, physical exertion, viral upper respiratory infections, or pharmacological agents (non-selective beta-blockers, aspirin, and non-steroidal anti-inflammatory drugs [NSAIDs]). A personal or family history of atopy (allergic rhinitis, atopic dermatitis) is common.
  • COPD is a progressive disorder characterised by persistent respiratory symptoms and persistent airflow obstruction that may improve partly with bronchodilators. It arises from chronic airway inflammation (bronchitis/bronchiolitis) and alveolar destruction (emphysema) driven predominantly by Th1T_h1 lymphocytes, CD8+ cytotoxic T cells, macrophages, and neutrophils in response to prolonged inhalation of noxious airborne particles. Tobacco smoking is a major risk factor. Other causes include occupational dusts, chemical fumes, biomass fuel smoke, and genetic deficiencies (such as homozygous α1\alpha_1-antitrypsin deficiency, PiZZ genotype). Patients typically present past the age of 40 with insidious, progressive exertional breathlessness, chronic productive morning cough, and frequent winter respiratory tract infections, with minimal day-to-day variability.

Diagnostic Spirometry and Reversibility Testing

Spirometry is the definitive diagnostic gold standard for establishing airflow limitation. Testing must be performed according to standardised ATS/ERS quality criteria before and after the administration of a rapid-acting inhaled bronchodilator (for example 200–400 mcg of inhaled salbutamol via spacer, with repeat spirometry after 10–15 minutes in GINA):

  1. Asthma confirmation. Start with a history of variable symptoms. In adults, GINA 2026 accepts an increase in FEV1FEV_1 or FVC of at least 12% and at least 200 mL from baseline as one way to show variable expiratory airflow. For example, an increase from 2.00 L to 2.24 L is 240 mL and 12%, so it meets both thresholds. One normal test does not exclude asthma. Repeat testing during symptoms if safe, measure twice-daily PEF variability over two weeks (average daily amplitude divided by mean >10% in adults), or arrange specialist bronchial challenge where indicated.
  2. Fractional exhaled nitric oxide (FeNO). With typical symptoms and unavailable or negative lung-function testing, FeNO >50 ppb in adults and adolescents (>35 ppb in children) supports Type 2 asthma under GINA 2026. Allergic rhinitis and other conditions can also raise FeNO. A lower value cannot exclude asthma. Smoking and corticosteroid treatment can reduce the result.
  3. COPD confirmation. GOLD requires post-bronchodilator FEV1/FVC<0.70FEV_1/FVC <0.70 in an appropriate clinical context. Repeat spirometry on another occasion if the ratio is between 0.60 and 0.80. Consider age and the lower limit of normal when interpreting a borderline ratio. The magnitude of acute bronchodilator response alone cannot distinguish asthma from COPD. A person can have persistent obstruction and credible evidence of both diseases.

GOLD Classification of Airflow Limitation in COPD

Once persistent airflow limitation has been established by a post-bronchodilator FEV1/FVC<0.70FEV_1 / FVC < 0.70, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) categorises the severity of airflow obstruction based on the post-bronchodilator FEV1FEV_1 percentage of predicted normal value:

GOLD StageSeverity ClassificationPost-Bronchodilator FEV1FEV_1 (% Predicted)
GOLD 1MildFEV1≥80%FEV_1 \ge 80\% of predicted
GOLD 2Moderate50%≤FEV1<80%50\% \le FEV_1 < 80\% of predicted
GOLD 3Severe30%≤FEV1<50%30\% \le FEV_1 < 50\% of predicted
GOLD 4Very SevereFEV1<30%FEV_1 < 30\% of predicted

In addition to spirometric staging, clinical assessment requires the integrated GOLD ABE Assessment Tool, which combines symptom burden (assessed by the modified Medical Research Council [mMRC] dyspnoea scale or COPD Assessment Test [CAT]) and the individual's exacerbation history:

  • Group A: Zero moderate or severe exacerbations in the previous year and lower symptom burden (CAAT/CAT <10 or mMRC 0–1).
  • Group B: Zero moderate or severe exacerbations with higher symptom burden (CAAT/CAT ≥10 or mMRC ≥2).
  • Group E: At least one moderate or severe exacerbation in the previous year, regardless of symptom score. This is the GOLD 2026 change from the earlier threshold of two moderate exacerbations or one admission.

Maintenance treatment and follow-up

Asthma. Provide ICS-containing treatment. GINA's preferred adult and adolescent route uses an appropriate low-dose ICS–formoterol reliever, with maintenance-and-reliever treatment at higher steps. Check the Irish product indication and formulation. An alternative uses a separate reliever with regular ICS-containing treatment. Check inhaler technique, adherence, exposure and comorbidities before increasing therapy. Offer a written action plan.

COPD. Support smoking cessation, vaccination and pulmonary rehabilitation as appropriate. In GOLD 2026, a bronchodilator is used for Group A and dual long-acting bronchodilation (LABA–LAMA) is generally preferred for Groups B and E. Consider initial triple therapy in Group E when blood eosinophils are at least 300 cells/µL. The eosinophil count helps predict the benefit of adding ICS for exacerbation prevention. If asthma coexists, include ICS and follow the asthma safety principles. Explain device use and review symptoms, exacerbations and adverse effects.

GINA 2026 strategy · GOLD 2026 report

Acute Asthma: Severity Stratification and Emergency Management

Acute exacerbations of asthma represent medical emergencies characterized by a progressive increase in symptoms of breathlessness, wheezing, coughing, or chest tightness, accompanied by decreases in expiratory airflow (PEF or FEV1FEV_1). Prompt objective assessment and protocol-driven escalation are essential to prevent fatal outcomes.

Severity Classification of Acute Asthma

Use the highest-risk finding and reassess after initial therapy. The following thresholds are from Ireland's NCEC Guideline 14 for patients aged 16 and over.

SeverityPEF as percentage of best or predictedFindings that change the response
Mild>75%Speaks in sentences, can lie flat, mild wheeze
Moderate50–75%May speak in phrases, with RR <25 and no severe or life-threatening finding
Severe33–50%Cannot complete a sentence in one breath, RR >25 or pulse >110 in the Irish severity table
Life-threatening<33% if measurableSpO₂ <92%, silent chest, cyanosis, weak respiratory effort, exhaustion, confusion, arrhythmia or hypotension
Near-fatalOften unable to perform PEFRaised arterial CO₂ in acute asthma or a requirement for ventilation, with urgent anaesthetic and critical-care input

Use previous best PEF when available. Treat while assessing if measurements would delay care. Obtain an ABG for SpO₂ below 92% or another life-threatening finding. Chest X-ray can help when a complication is suspected, initial treatment fails or ventilation is required.

Important

A tachypnoeic patient with severe airflow obstruction generally lowers their PaCO2PaCO_2 through hyperventilation. A normal value in that setting can signal failing ventilation. Escalate for this life-threatening warning and trend the gases alongside effort and consciousness. A rising or frankly elevated PaCO2PaCO_2 requires emergency specialist assessment.

Initial treatment and escalation

  1. Oxygen for hypoxaemia. NCEC 14 targets SpO₂ 94–98% in hypoxaemic severe adult asthma. Give oxygen promptly and titrate to oximetry. The newer GINA 2026 international acute pathway starts supplemental oxygen below 92% and targets 92–95% in patients aged six and over. Use the target specified by the clinical setting and reassess.
  2. Inhaled bronchodilator. Give salbutamol promptly. A metered-dose inhaler with spacer is effective in milder attacks. For life-threatening asthma the Irish protocol uses oxygen-driven salbutamol 5 mg nebulised. Repeat according to response and local protocol. In poorly responsive severe asthma, discuss continuous nebulisation with senior staff and monitor for tachycardia, hypokalaemia and treatment-related lactate elevation.
  3. Ipratropium. Add 500 mcg nebulised in severe or life-threatening asthma or after a poor initial response to salbutamol. Reassess the need for repeat doses.
  4. Systemic corticosteroid. Give oral prednisolone 40–50 mg early and continue for at least five days or until recovery under the Irish adult protocol. If oral treatment cannot be taken reliably, the Irish hospital protocol uses hydrocortisone 100 mg IV every six hours. Continue or start appropriate inhaled corticosteroid therapy.
  5. Magnesium and senior review. Discuss a single dose of IV magnesium sulfate 1.2–2 g over 20 minutes if severe asthma responds poorly to initial inhaled treatment or if life-threatening or near-fatal features are present. IV aminophylline is an exceptional senior decision because of toxicity and limited additional benefit. Routine antibiotics have no role without a separate indication.
  6. Disposition. Call anaesthetics and critical care early for life-threatening findings, falling effort, worsening hypoxaemia or CO₂ retention. Admit any life-threatening attack or severe features persisting after initial treatment. Before discharge after recovery, check technique and controller treatment, provide a written action plan, and arrange GP follow-up within two working days after ED or hospital discharge in the Irish pathway.

Irish adult acute asthma guideline · GINA 2026 acute care pathway

Acute Exacerbation of COPD (AECOPD): Stepwise Protocol

An acute exacerbation of COPD is an increase in dyspnoea and/or cough and sputum over up to 14 days. Assess severity and look for triggers or mimics such as pneumonia, heart failure, PE and pneumothorax.

Controlled Oxygen Therapy: Avoiding Hyperoxic Hypercapnia

In acute exacerbations of COPD, uncontrolled high-flow oxygen can precipitate lethal hypercapnic respiratory failure and coma. The target oxygen saturation in AECOPD is initially 88–92% when oxygen is needed and hypercapnia is possible. Check blood gases and consider a documented patient-specific target or senior advice.

Three distinct physiological mechanisms explain oxygen-induced hypercapnia:

  1. Worsening of Ventilation-Perfusion (V/QV/Q) Mismatch (Primary Mechanism): Hypoxic pulmonary vasoconstriction redirects pulmonary blood flow away from poorly ventilated alveoli toward well-ventilated regions. High oxygen concentrations can reverse this vasoconstriction and worsen the distribution of blood flow relative to ventilation. The resulting gas-exchange inefficiency contributes to a rise in PaCO2PaCO_2.
  2. The Haldane Effect: Deoxygenated haemoglobin has a higher affinity for carbon dioxide than oxygenated haemoglobin. Rapid oxygen saturation of haemoglobin displaces CO2CO_2 molecules into blood plasma, acutely raising dissolved arterial PaCO2PaCO_2.
  3. Blunting of Hypoxic Ventilatory Drive: In patients with long-standing severe hypercapnia, central medullary chemoreceptors become desensitised to chronically elevated PaCO2PaCO_2 due to renal retention of bicarbonate (HCO3−HCO_3^-). A fall in minute ventilation can also contribute. The main clinical issue is uncontrolled oxygen delivery, which can raise CO₂ through several mechanisms.

Controlled Delivery: Initiate oxygen via a 24% or 28% Venturi mask at the flow specified on the device (or low-flow nasal cannulae if suitable). Perform a baseline arterial blood gas (ABG) and repeat the ABG within 30–60 minutes after starting or adjusting therapy, and sooner if the patient deteriorates, to ensure the PaCO2PaCO_2 is not rising and the arterial pH remains stable.

Bronchodilator Therapy in AECOPD

  • Give a short-acting beta₂ agonist, with or without a short-acting muscarinic antagonist. For example, use nebulised salbutamol 2.5–5 mg with ipratropium 500 mcg when a nebuliser is indicated, or a metered-dose inhaler with spacer when suitable.
  • Use compressed air for nebulisation in patients at risk of hypercapnia, with supplemental oxygen separately titrated if needed. If air is unavailable during ambulance transport, BTS permits a brief oxygen-driven nebuliser in known COPD, limited to six minutes, then return to controlled oxygen. Maintain appropriate oxygenation throughout treatment.

Systemic corticosteroids

For adults presenting to hospital with acute COPD exacerbation, Irish NCEC Guideline 27 recommends oral prednisolone 40 mg once daily for five days. In REDUCE, five days of prednisone 40 mg was noninferior to 14 days for re-exacerbation over six months and reduced total steroid exposure. Hyperglycaemia and hypertension did not differ significantly between groups.

Antibiotics and sputum findings

Increased dyspnoea, sputum volume and purulence are the three cardinal symptoms used in the Anthonisen study. In Irish practice, consider antibiotics when increased dyspnoea accompanies increased sputum volume or purulence. Purulence supports bacterial infection. Weigh clinical severity, alternative diagnoses, previous cultures and treatment failure risk. Severe exacerbations requiring ventilation also merit assessment for antibiotics.

For an appropriate adult treated in the community, the HSE AMRIC guideline lists amoxicillin 500 mg every eight hours for five days. Doxycycline is preferred in penicillin allergy (200 mg daily or 100 mg every 12 hours for five days, with a lower maintenance dose after a 200 mg first dose an option for non-severe infection). Clarithromycin 500 mg every 12 hours for five days is an alternative in penicillin allergy after checking interactions and existing azithromycin use. Review the guidance for pregnancy, recent antibiotics, known resistant organisms and severe illness.

Irish NCEC COPD guideline · HSE community antibiotic guideline · REDUCE trial · Anthonisen trial

Non-Invasive Ventilation (NIV / BiPAP) in Acute Hypercapnic Respiratory Failure

Non-Invasive Ventilation using Bilevel Positive Airway Pressure (BiPAP) is an established, life-saving intervention that reduces intubation rates, hospital length of stay, and in-hospital mortality in patients with acute hypercapnic respiratory failure (Type 2 respiratory failure) secondary to AECOPD.

Physiological Mechanism of BiPAP

BiPAP delivers two distinct pressure levels through a tightly fitting oronasal or full-face mask synchronized with the patient's spontaneous breathing:

  1. Inspiratory Positive Airway Pressure (IPAP): Provides pressure support during inspiration, augmenting alveolar tidal volume (VTV_T), increasing minute ventilation, actively blowing off carbon dioxide (CO2CO_2), and unloading the fatigued diaphragm and accessory muscles.
  2. Expiratory Positive Airway Pressure (EPAP): Maintains positive pressure during exhalation, preventing terminal airway collapse, recruiting micro-atelectatic alveolar units, improving oxygenation, and counterbalancing intrinsic positive end-expiratory pressure (auto-PEEP), which reduces the muscular work required to trigger subsequent breaths.

Clinical Indications for Acute NIV

Irish NCEC Guideline 27 recommends NIV for acute COPD respiratory failure with arterial pH <7.35 and PaCO2PaCO_2 >6 kPa persisting after correction of inappropriate oxygen delivery. Begin controlled oxygen and bronchodilators, obtain an early ABG, and reassess promptly. Severe or worsening acidosis, exhaustion or deteriorating consciousness requires immediate senior and critical-care assessment. Base timing on the patient's condition.

Starting NIV and judging response

  • Bilevel pressure support is the difference between IPAP and EPAP. At IPAP 15 and EPAP 5 cmH₂O, pressure support is 10 cmH₂O. Increasing IPAP to 20 at the same EPAP raises support to 15 cmH₂O and may improve ventilation if leak and synchrony are controlled.
  • Use the local NIV protocol and a monitored setting. Adjust the interface and pressures according to comfort, leak, chest movement, respiratory rate, oxygenation and gases. Give oxygen to maintain SpO₂ 88–92% in acute hypercapnic failure. Repeat gases promptly after starting NIV, often within an hour, and sooner if the patient deteriorates.
  • An improving pH and respiratory rate support continued NIV. If acidosis or exhaustion worsens, review mask leak and settings immediately and assess for intubation. Plan escalation and discuss the ceiling of treatment before or at initiation.
FindingImplication
Cardiorespiratory arrest, inadequate spontaneous ventilation, or inability to protect the airwayImmediate resuscitation and airway support
Active vomiting, fixed upper airway obstruction or facial trauma preventing mask fitUrgent specialist airway strategy
Acute pneumothoraxTreat first, with emergency decompression if tension is suspected
Hypercapnic drowsiness with preserved airway protection, heavy secretions, agitation, circulatory instability or severe acidosisHigh risk of NIV failure. Critical-care supervision and immediate access to intubation if a trial is appropriate

Irish NCEC COPD guideline · BTS/ICS acute ventilatory support · BTS emergency oxygen guidance

Loading diagram...
AECOPD Acute Hypercapnic Respiratory Failure and NIV Management Pathway
Test Your Knowledge

A 24-year-old woman with a history of atopic asthma presents to the emergency department with acute breathlessness and chest tightness. On examination, she is tachypnoeic at 28 breaths/min and tachycardic at 118 bpm. She is unable to speak in full sentences, using accessory neck muscles during respiration. Bilateral expiratory wheeze is auscultated throughout all lung fields. Her peak expiratory flow (PEF) is 210 L/min (42% of predicted). An arterial blood gas on ambient air reveals: pH 7.41, PaCO2 4.8 kPa (36 mmHg), PaO2 9.2 kPa (69 mmHg), and HCO3 22 mmol/L. Using the Irish adult acute asthma approach, which classification best categorises her exacerbation, and what is the primary clinical significance of her arterial blood gas findings?

A

Moderate asthma exacerbation; the normal PaCO2 demonstrates preserved alveolar ventilation and reassuring respiratory mechanics.

B

Life-threatening asthma exacerbation. A normal PaCO₂ despite severe obstruction and tachypnoea is a warning of failing ventilation.

C

Severe asthma exacerbation; the normal PaCO2 confirms that standard back-to-back bronchodilator nebulisation alone will achieve rapid resolution without specialist referral.

D

Near-fatal asthma exacerbation; the arterial blood gas indicates severe decompensated alveolar hypoventilation requiring immediate emergency endotracheal intubation.

Test Your Knowledge

A 68-year-old man with severe COPD (GOLD 4) is brought to the emergency department by ambulance with worsening breathlessness, increased cough, and fever. Paramedics administered oxygen via a 15 L/min non-rebreather reservoir mask during transit. On arrival, he is awake, follows instructions, clears his secretions and protects his airway. He is haemodynamically stable, with a respiratory rate of 30 breaths/min. Arterial blood gas analysis on the high-flow oxygen reveals: pH 7.24, PaCO2 9.8 kPa (73.5 mmHg), PaO2 14.5 kPa (108.8 mmHg), and HCO3 31 mmol/L. After oxygen titration and initial bronchodilators he remains acidotic and tachypnoeic. Critical care is present and can intubate if required. What is the next ventilatory strategy?

A

Increase oxygen delivery to 100% via mechanical bag-valve-mask and administer an intravenous sodium bicarbonate infusion to correct severe acidaemia.

B

Continue high-flow oxygen via the non-rebreather mask, administer intravenous doxapram as a respiratory stimulant, and delay ventilatory support for 2 hours.

C

Continue controlled oxygen and commence monitored bilevel NIV, with prompt reassessment and an intubation plan if it fails.

D

Perform immediate emergency endotracheal intubation and transfer to the intensive care unit without attempting non-invasive ventilation.

Test Your Knowledge

A 71-year-old man with known COPD attends his GP reporting a 3-day history of worsening exertional breathlessness and an increased quantity of sputum. He notes that the sputum remains clear and white (mucoid), identical to his baseline appearance. On examination, he is afebrile with a temperature of 36.8°C, respiratory rate 20 breaths/min, pulse 80 bpm, blood pressure 130/80 mmHg, and oxygen saturation 91% on room air. Chest auscultation reveals quiet breath sounds with scattered expiratory wheeze. There are no focal signs or other findings suggesting pneumonia. How does current HSE community guidance use the sputum findings in the antibiotic decision?

A

Consider an oral antibiotic after assessing severity and other causes because both dyspnoea and sputum volume have increased.

B

Withhold antibiotics in every case where sputum stays mucoid, regardless of breathlessness and sputum volume.

C

Prescribe intravenous co-amoxiclav 1.2 g three times daily; hospital assessment for COPD exacerbation mandates broad-spectrum coverage for Pseudomonas aeruginosa.

D

Prescribe oral clarithromycin 500 mg twice daily for 14 days to provide long-term immunomodulatory anti-inflammatory suppression.

Sections you finish are checked off in the contents.